BridgeBio raises $1B via preferred equity from Sixth Street and KKR's HealthCare Royalty, stockpiling cash ahead of three drug launches within 18 months.
July 1, 2026 10:29 AM EDT
Financing
BridgeBio adds $1B as it prepares three more drug launches
Kyle LaHucik
Biotech Correspondent
BridgeBio attracts $1B in equity for new launches, but analyst smells M&A ‘dry powder’
BridgeBio gets funding for drug launch; United buys into cell therapy
More signs that GLP-1s may help with peripheral artery disease
Beeline ups its Series A round for immune drug work
Things are happening fast at BridgeBio as it plugs away at the launch of blockbuster-in-waiting Attruby and prepares to…
Elsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded…
Nonprofit Blood Cancer United acquires cancer drug, Lilly and Nvidia invest in Abridge, and more biotech news
As Alnylam’s Amvuttra sales disappointed, revenue from BridgeBio’s rival transthyretin amyloidosis (ATTR) drug Attruby came in…
Biogen pays up to $1B for secretive San Diego biotech RayThera, gaining three undisclosed anti-inflammatory candidates to expand…
Caldera-Synlogic and Vidya-Processa ink reverse mergers with Bain-backed placements, advancing a TL1A bispecific and a BTK…
